Overview

Beta Pharma is a clinical stage discovery biopharmaceutical company that develops novel small molecule therapeutics of known molecular targets and biological pathways for the treatment of cancer, diabetes and viral diseases. Our business model combines creativity and innovation with efficient R&D process by leveraging expertise and capabilities in both US and China. We focus our efforts on generating next generation compounds against drugable proven targets with better efficacy or safety profiles. Working synergistically between US and China divisions we aim to develop a “fast track” system for IND filing and gaining POC in human.

Beta Pharma China is one of the first few biotech companies in China that have advanced a novel product into late phase clinical development. Our lead product icotinib has completed Ph2 development and initiated Ph3 in China for NSCLC. Other promising products of our Pipelines in earlier stage of development include novel multi-kinase inhibitor and PARP antagonist for cancer, GLP-1 analogue and DPP IV inhibitors for diabetes.